Navigation Links
Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
Date:8/3/2009

omib and dexamethasone in heavily pre-treated patients with relapsed and refractory disease. Given this positive data and our favorable experience overall with perifosine in this setting, we are hopeful that the upcoming Phase 3 trial will demonstrate clinical benefit for our patients with less advanced myeloma."

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We'd like to thank the FDA and Drs. Paul Richardson and Ken Anderson for their substantial input and guidance during this process. Achievement of this KRX-0401 SPA is a major developmental milestone for Keryx." Mr. Bentsur continued, "We are excited to be moving forward with this very promising compound which we believe is the most advanced PI3K/Akt pathway inhibitor in clinical development."

Phase 3 Design

The Phase 3 trial is a randomized (1:1), double-blind trial comparing the efficacy and safety of KRX-0401 to placebo when combined with bortezomib and dexamethasone in approximately 400 patients with relapsed or relapsed / refractory multiple myeloma. Patients must have been previously treated with both bortezomib (VELCADE((R))) and an immunomodulatory agent (REVLIMID((R)) or THALIDOMID((R))), and been previously treated with one to four prior lines of therapy. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. in the United States, Canada and Mexico.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,50
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
2. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
11. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... which patients might suffer potentially fatal side-effects from a ... brain scans using pattern recognition software similar to that ... developed by researchers at Imperial College London. Results of ... used the software are published in the journal ... million people each year worldwide. Ischemic strokes are the ...
(Date:4/23/2014)... a country as wealthy as the United States, it may ... not have access to adequate food due to lack of ... , Recent research at the University of Illinois using data ... that the seniors who are dealing with hunger are also ... 8.35 percent of Americans over age 60 faced the threat ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... a movie may induce enough stress to interfere with ... time you sit down to watch a violent or ... problem-solving ability. ,David Beversdorf, a neurologist at the ... women and asked them to combine movie viewing with ...
... develop complications with the placenta during pregnancy appear to ... // . ,The study, published in the ... risk of premature cardiovascular disease doubled when she had ... gestational high blood pressure and separation of the placenta ...
... considered as an important breakthrough in our still limited ... new gene linked to major mental illness // ... to increase the risk of schizophrenia and depression. ... together with scientists from the pharmaceutical company Merck, Sharp ...
... professional colleges regarding the issue of having a common ... // . Few educational institutions are under the opinion ... marks alone. ,Following the judgment of the Supreme ... upon admission on their own, an entity called All ...
... anthrax outbreak in Makassar, Indonesia, has infected at least five ... Post // . ,The human infections came to light ... in Tamangapa subdistrict have died of anthrax recently. ... the five persons after it was discovered that the cattle ...
... chill was just starting to set in when the world's ... down a ramp under a starry sky at a show ... awareness.// ,Glebova was also joined by Miss ... the show here Wednesday night to promote awareness about AIDS., ...
Cached Medicine News:Health News:A Step Towards Unraveling The Schizophrenia And Depression Mystery 2Health News:Mixed Opinion Regarding Common Medical And Engineering Entrance Test 2Health News:Five People Treated For Anthrax In Indonesia 2Health News:Miss Universe Walks The Ramp For AIDS Awareness 2
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... ANAHEIM, Calif. , July 28 Siemens ... services and solutions for clinicians at the American Association for ... from July 27 through July 29, 2010 ... demonstrating how Siemens is focused on putting the power behind ...
... Commitment to Patient Safety; Approved Sites Eligible to Advertise through Search ... , , ... 28 The National Association of Boards of Pharmacy ® ... Drug as the first online pharmacy services to be approved through ...
Cached Medicine Technology:Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 2Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 3Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 4Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 5Siemens Showcases Broad Array of Innovative Diagnostic Solutions at 2010 AACC and ASCLS Annual Meetings and Clinical Lab Expo 6NABP Grants First 'Approved e-Advertiser' Status to Pharmahelper.com, QC Supply, and Kerr Drug 2NABP Grants First 'Approved e-Advertiser' Status to Pharmahelper.com, QC Supply, and Kerr Drug 3
... microplate incubator is an extremely compact ... single microplate up to 50C. ... requiring higher temperatures up to 65C. ... low cost and high performance for ...
... The Solo microplate incubator is an ... incubating a single microplate up to ... incubates applications requiring higher temperatures up ... solution offering low cost and high ...
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... is available as a one-cabinet ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Medicine Products: